How to Improve Your Success in Treating Mild and Moderate Inflammatory Bowel Disease

Summary of presentations from the Tillotts Pharma-sponsored Satellite Symposium on Inflammatory Bowel Disease, held in Amsterdam, Netherlands, on 18th March 2016

Chairperson: Geert D’Haens1
Speakers: Ailsa Hart,2 Pieter Hindryckx3

1. Academic Medical Centre-IBD Unit, University of Amsterdam, Amsterdam, Netherlands
2. Director, IBD Unit, St Mark’s Hospital, London, UK
3. Research Gastroenterologist, Department of Gastroenterology, University Hospital of Ghent, Ghent, Belgium

Disclosure: Within the last 3 years, Pieter Hindryckx has received advisory board fees from AbbVie; speakers fees from Ferring, Falk Pharma, Vifor Pharma, Tillotts Pharma, Takeda, and AbbVie. Ailsa Hart has lectured/attended advisory boards for AbbVie, MSD, Hospira, Napp pharmaceuticals, Ferring, Tillotts, Warner Chilcott, Yakult, Atlantic, BMS, and Pfizer.
Acknowledgements: Writing assistance was provided by Lynsey Stevenson, Ashfield Healthcare Communications Ltd.
Support: The publication of this article was funded by Tillotts Pharma. The views and opinions expressed are those of the speakers and not necessarily of Tillotts Pharma.
Citation: EMJ Gastroenterol. 2016;5[Suppl 8]:2-9.

Meeting Summary

Inflammatory bowel disease (IBD) describes two inflammatory conditions of the gastrointestinal tract: ulcerative colitis (UC) and Crohn’s disease (CD). For patients with UC, chronic inflammation of the rectum and colon results in faecal urgency, recurring diarrhoea, and abdominal pain. For patients with CD, mucosal inflammation may occur anywhere along the gastrointestinal tract and common symptoms may include diarrhoea, abdominal pain, fatigue, and weight loss. The vast majority of patients with IBD have mild-to-moderate disease at diagnosis: 85% of patients with UC and 70−80% of patients with CD. Evidence-based guidelines for the management of UC recommend 5-aminosalicylic acid (ASA) treatment (mesalazine) as a first-line therapy. There is evidence to suggest that 5-ASA treatment can be optimised in patients with mild-to-moderate UC by optimising the dose, combining oral with rectal therapy, and increasing treatment duration. For ileocaecal CD, guidelines recommend budesonide as a first-line treatment for mildly and moderately active disease. Systemic corticosteroids may be prescribed as an alternative to budesonide in patients with moderately active disease and as initial therapy in severely active disease. As with all chronic therapies, poor adherence impacts treatment efficacy in IBD as a result of a number of patient and treatment-related factors. Approaches to improve adherence include boosting patient motivation and education and reducing treatment complexity. Key factors for ensuring successful treatment of both UC and CD include understanding predictors of outcome, selection of the right drug, at the right dose, at the right time, and having well-informed and motivated patients.

Click below to view the following videos:
Success factors in the treatment of mild-to-moderate UC by Dr Ailsa Hart during the 11th Congress of ECCO
Success factors in the treatment of uncomplicated CD by Dr Pieter Hindryckx during the 11th Congress of ECCO
Discussion on mild and moderate IBD treatment led by Prof Geert D’Haens during the 11th Congress of ECCO
Click here
to visit the Tillotts’ website.

Download (PDF, 135KB)

Comments are closed.